A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients

Early Stage Breast Cancer Clinical Trial

Official title:

A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx™ System Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03561454
• Other study ID #: 20180335
• Status: Active, not recruiting
• Start date: January 11, 2019
• Est. completion date: August 1, 2029

Study information

• Verified date: March 2023
• Source: MedStar Franklin Square Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Single arm, prospective, multi-center, non-randomized study of subjects treated with single fraction, intra-operative radiation therapy at the time of lumpectomy for early stage breast cancer.To assess the rate of ipsilateral breast tumor recurrence in subjects treated with the Xoft Axxent Electronic Brachytherapy System when used for single-fraction, intra-operative radiation therapy treatment of early stage breast cancer when compared to whole breast irradiation (WBI) at 5 years of follow-up. The results of this single arm study will be compared to whole breast irradiation (WBI).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: August 1, 2029
• Est. primary completion date: August 1, 2028
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 40 Years to 100 Years

Eligibility

General Inclusion Criteria

1. Subject must have provided written Informed Consent

2. Subject must have biopsy-proven ductal carcinoma in situ (DCIS) or invasive ductal carcinoma of the breast a. In addition to invasive ductal carcinoma, allowable invasive carcinomas are: i. Adenoid cystic (or adenocystic) carcinoma ii. Low-grade adenosquamous carcinoma iii. Medullary carcinoma iv. Mucinous (or colloid) carcinoma v. Papillary carcinoma vi. Tubular carcinoma vii. Metaplastic carcinoma viii. Micropapillary carcinoma ix. Mixed carcinoma

3. Subject must be female = 40 years of age

4. Subject's tumor(s) must be < 3.0 cm in greatest diameter by pre-operative assessment

5. Clinical staging of Subject's tumor(s) must meet AJCC Tumor Classification: Tis, T1 or T2 (< 3 cm), N0, M0

6. Subject presenting with bilateral breast cancer may be enrolled if BOTH cancers meet all of the inclusion and none of the exclusion criteria

7. Women of child-bearing potential must have a negative pregnancy test within one week of IORT treatment

8. Women of child-bearing potential must agree to use adequate contraceptive precautions (defined as intrauterine devices, surgical contraceptives or a combination of condom and spermicide) from the time of negative pregnancy test through completion of the radiation treatment period General Exclusion Criteria

1. Subject is pregnant or nursing

2. Subject has significant auto-immune disease

3. Subject has a pacemaker present in the field of radiation or quadrant of the breast cancer

4. Subject has multi-focal breast cancer where the sum of the individual tumor sizes (greatest diameters) are > 3 cm Subject has multi-centric breast cancer

5. Subject has known lympho-vascular invasion

6. Subject has invasive lobular cancer

7. Subject has undergone neo-adjuvant chemotherapy or neo-adjuvant endocrine therapy for current breast cancer

8. Subject has a history of recurrent breast cancer in the ipsilateral breast

9. Subject has had previous radiation exposure of the involved breast

10. Subject has BRCA 1 or 2 mutations. Note: Testing will only be required for subjects presenting with bilateral breast cancer; testing is not required for unilateral cancers

11. Subject has contraindications for radiation

12. Subject considered by the Investigator to be high-risk for breast conservation surgery and/or intra-operative radiation therapy

13. Subject has participated in any other clinical investigation that is likely to confound study results or affect study outcome either at the time of IORT or for 3 months prior to IORT

Related Conditions & MeSH terms

• Early Stage Breast Cancer

Intervention

Device:
• IORT
Intra-Operative Radiation Therapy

Locations

Country	Name	City	State
United States	MedStar Good Samaritan Hospital	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
MedStar Franklin Square Medical Center	Medstar Health Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	tumor recurrence		5 years